作者: Makoto Ohsawa , Yukiko Tanaka , Yoshito Ehara , Setsuko Makita , Kosuke Onaka
DOI: 10.3233/ADR-170026
关键词:
摘要: A recent classification analysis of neuropsychiatric symptoms in patients with Alzheimer's disease (AD) revealed a distinct cluster apathy and eating problems including anorexia that exhibits frailty. The frailty are risk factors the progresses. However, there is currently no effective drug for treating both AD. Here, we conducted an open-label pilot study to determine whether ninjin'yoeito (NYT, TJ-108), multicomponent drug, improving AD, consequently their cognitive function. Trials were at three sites Japan. Twenty [4 men 16 women, average age = 82.6±7.7 (mean±SD) years old], 19 AD 1 mixed dementia anorexia/apathy, examined. NYT (6-9 g/day) was administered 12 weeks. changes scores "anorexia" using Neuropsychiatric Inventory (NPI) subcategory disturbance (primary outcome measure), NPI "apathy", vitality index, Mini-Mental State Examination (MMSE), physical blood nutrition indices evaluated baseline (week 0), weeks 4, 8 12. After week significant improvements observed "apathy" by meal ingestion amount. Vitality index MMSE score significantly improved We propose NYT, several effects dopamine modulation, new-type therapeutic agent low adverse reactions can improve simultaneously as well dysfunction frail patients.